<DOC>
	<DOCNO>NCT02809534</DOCNO>
	<brief_summary>To assess primary effect safety Anlotinib placebo patient Hepatocellular Carcinoma ( HCC ) .</brief_summary>
	<brief_title>A Study Anlotinib Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Conform clinical diagnosis standard strictly histological cytological confirmation hepatocellular carcinoma benefit treatment ablative therapy Liver function status ChildPugh Class A B ( score≤8 ) Enroll 2 group patients：Group A：No history systematic chemotherapy/target therapy.Group B : Failed Sorafenib ( Last Sorafenib Therapy≥4 week ) Last Therapy≥4 week ( surgery , PCI , ablation , radiotherapy ) ，and wound healing.Patients adjuvant chemotherapy , last chemotherapy ≥6m At least one measurable lesion ( RECIST1.1 ) 1875 year , ECOG PS:01 , Life expectancy 3 month Main organ function normal Women childbearing potential agree use utilize adequate method contraception ( intrauterine device，contraceptive condom ) throughout treatment least 6 month study stopped；the result serum urine pregnancy test negative within 7 day prior study enrollment，and patient require nonlactating；Man participant agree use utilize adequate method contraception throughout treatment least 6 month study stop Patients participate study voluntarily sign informed consent Diagnosed cholangiocellular carcinoma , mixed cell carcinoma fibrolamellar hepatocellular carcinoma History malignancy ( except nonmelanoma skin cancer , cervix situ carcinoma ) Liver function status ChildPugh Class C ( score &gt; 9 ) , malignant ascites HBVDNA &gt; 2000IU/mL History liver transplantation prepare Patients severe and/or unable control diseases，including： 1 . Blood pressure unable control ideally ( systolic pressure≥150 mmHg，diastolic pressure≥100 mmHg ) ; 2 . Patients Grade 1 high myocardial ischemia , myocardial infarction malignant arrhythmia ( include QT≥480ms ) patient Grade 1 high congestive heart failure ( NYHA Classification ) ; 3 . Patients active unable control serious infection ; 4 . Patients poorly control diabetes ( fast blood glucose ( FBG ) ＞10mmol/L ) 5 . Urine protein ≥ ++，and 24hour urinary protein excretion＞1.0 g confirm Patients arterial venous thromboembolic event occur within 6 month , cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism Patients drug abuse history unable get rid Patients mental disorder Imaging show tumor involve important blood vessel investigator determine likely followup study cause fatal hemorrhage Patients participate anticancer drug clinical trial within 4 week History immunodeficiency Patients concomitant disease could seriously endanger safety could affect completion study accord investigator ' judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Anlotinib</keyword>
	<keyword>AL3818</keyword>
</DOC>